Gamida Cell Announces FDA Acceptance of Biologics License Application for Omidubicel with Priority Review
If approved, omidubicel will be the first allogeneic advanced stem cell therapy donor source for patients with blood cancers in need of a stem cell transplant
PDUFA target action date is January 30, 2023
BOSTON--(BUSINESS WIRE)--Aug. 1, 2022--...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news
More News: Cancer | Cancer & Oncology | Drugs & Pharmacology | New Drug Applications | Stem Cell Therapy | Stem Cells | Transplants